ANI Pharmaceuticals Future Growth
Future criteria checks 3/6
ANI Pharmaceuticals is forecast to grow earnings and revenue by 34.9% and 6.6% per annum respectively while EPS is expected to grow by 35% per annum.
Key information
34.9%
Earnings growth rate
35.0%
EPS growth rate
Pharmaceuticals earnings growth | 22.8% |
Revenue growth rate | 6.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 07 Aug 2024 |
Recent future growth updates
Recent updates
ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Aug 02Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
Jun 10ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Jun 10These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings
Nov 15Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Feb 22We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt
Oct 28ANI Pharma launches generic Prochlorperazine maleate tablets
Aug 29ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval
Aug 16ANI Pharmaceuticals Q2 2022 Earnings Preview
Aug 05ANI Pharmaceuticals (NASDAQ:ANIP) Is Making Moderate Use Of Debt
Apr 29Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 662 | 65 | 121 | 180 | 4 |
12/31/2025 | 641 | 35 | 102 | 144 | 5 |
12/31/2024 | 569 | 27 | 99 | 105 | 5 |
6/30/2024 | 539 | 23 | 94 | 113 | N/A |
3/31/2024 | 517 | 31 | 95 | 116 | N/A |
12/31/2023 | 487 | 15 | 100 | 119 | N/A |
9/30/2023 | 449 | 10 | 53 | 70 | N/A |
6/30/2023 | 401 | -8 | 19 | 41 | N/A |
3/31/2023 | 359 | -28 | -7 | 9 | N/A |
12/31/2022 | 316 | -50 | -48 | -31 | N/A |
9/30/2022 | 283 | -69 | -53 | -39 | N/A |
6/30/2022 | 251 | -65 | -52 | -48 | N/A |
3/31/2022 | 226 | -63 | -61 | -36 | N/A |
12/31/2021 | 216 | -43 | -20 | 3 | N/A |
9/30/2021 | 212 | -22 | -16 | 10 | N/A |
6/30/2021 | 213 | -17 | -17 | 14 | N/A |
3/31/2021 | 213 | -15 | 23 | 34 | N/A |
12/31/2020 | 208 | -23 | -53 | 15 | N/A |
9/30/2020 | 199 | -24 | -42 | 26 | N/A |
6/30/2020 | 198 | -20 | -15 | 49 | N/A |
3/31/2020 | 203 | -1 | -32 | 33 | N/A |
12/31/2019 | 207 | 6 | 18 | 46 | N/A |
9/30/2019 | 216 | 16 | 41 | 68 | N/A |
6/30/2019 | 215 | 17 | 28 | 55 | N/A |
3/31/2019 | 208 | 14 | 30 | 58 | N/A |
12/31/2018 | 202 | 15 | 56 | 67 | N/A |
9/30/2018 | 192 | 0 | -4 | 56 | N/A |
6/30/2018 | 189 | 0 | 3 | 64 | N/A |
3/31/2018 | 187 | 0 | N/A | 56 | N/A |
12/31/2017 | 177 | -1 | N/A | 39 | N/A |
9/30/2017 | 168 | 7 | N/A | 36 | N/A |
6/30/2017 | 158 | 5 | N/A | 20 | N/A |
3/31/2017 | 145 | 4 | N/A | 23 | N/A |
12/31/2016 | 129 | 4 | N/A | 27 | N/A |
9/30/2016 | 108 | 8 | N/A | 20 | N/A |
6/30/2016 | 90 | 10 | N/A | 29 | N/A |
3/31/2016 | 78 | 12 | N/A | 27 | N/A |
12/31/2015 | 76 | 15 | N/A | 17 | N/A |
9/30/2015 | 79 | 33 | N/A | 23 | N/A |
6/30/2015 | 77 | 35 | N/A | 17 | N/A |
3/31/2015 | 64 | 30 | N/A | 18 | N/A |
12/31/2014 | 56 | 29 | N/A | 22 | N/A |
9/30/2014 | 45 | 11 | N/A | 8 | N/A |
6/30/2014 | 36 | 5 | N/A | 3 | N/A |
3/31/2014 | 35 | 1 | N/A | 0 | N/A |
12/31/2013 | 30 | -5 | N/A | -5 | N/A |
9/30/2013 | 25 | -12 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANIP's forecast earnings growth (34.9% per year) is above the savings rate (2.5%).
Earnings vs Market: ANIP's earnings (34.9% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: ANIP's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ANIP's revenue (6.6% per year) is forecast to grow slower than the US market (8.5% per year).
High Growth Revenue: ANIP's revenue (6.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ANIP's Return on Equity is forecast to be high in 3 years time